Investing in Psychedelics: The "New Cannabis" for Investors

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Real VisionMay 04, 2021
Psychedelics have been studied for decades, and investors are starting to take note this year with increased public awareness around mental health issues from the Covid-19 pandemic and more support from clinical research that proves the potential for doctor-prescribed drugs like psilocybin, ketamine, and MDMA to hold significant promise as therapeutics for depression, anxiety, addiction, and PTSD. Steve Hawkins, president and CEO of Horizons ETFs, recently launched the world’s first psychedelics ETF, providing investors with a new way to get exposure to this emerging healthcare sector. Horizons ETFs is one of Canada's largest ETF companies and the firm behind the world’s first marijuana ETF and the world’s first inverse Bitcoin ETF. Filmed April 28, 2021. Key Learnings: In 2019, the psychedelics industry was valued at approximately $2 billion US dollars. By 2027, it’s predicted that the sector will reach a market cap of nearly $7 billion. There are more than a dozen publicly traded psychedelic companies, several of which are on the Canadian market. MindMed and Compass Pathways are the first and only psychedelics companies to be listed in the U.S. on the Nasdaq. Big pharmaceutical companies have also entered the space such as Johnson & Johnson and AbbVie.
Get access to daily trading ideas, trending topics, interviews and more!
Please subscribe to Canadian Insider Club Ultra

More Ultra Money Videos

Real VisionJuly 23, 2021
Raoul Pal & Julian Brigden: Diving into the Macro
Along with Real Vision senior editor Ash Bennington, Real Vision CEO and co-founder Raoul Pal welcomes Julian Brigden, co-founder of MI2 Partners, for his Real Vision Daily Briefing debut. As a special edition of the Daily Briefing, Pal and Brigden will be diving deep into their respective frameworks, discussing the differences in how they’re seeing the macro picture as well as rallying around where they are aligned.
"Reading the Soup" as a Crypto VC Firm
Picking the big fish in the sea of crypto is no easy task—George McDonaugh, co-founder and managing director of KR1 plc, and Keld van Schreven, co-founder and managing director of KR1 plc, join Real Vision CEO and co-founder Raoul Pal to share their expertise on early investing. Growing their company to a market cap of over $147 million, van Schreven and McDonaugh are both veterans in the investment space, dating back to the pre-Dot-Com era. With multiple 100x investments made through KR1, they give us a preview into the decision process that goes on behind the scenes, the consequences of being too early, and a fascinating discussion on the future of community-based economies. Filmed on July 14, 2021.
Real VisionJuly 23, 2021
The Interview: Brian Higgins and Raoul Pal
Brian Higgins of King Street Capital joins Real Vision CEO and co-founder Raoul Pal on the Interview.

Get a Canadian Insider Club Ultra subscription for

  • Insider filing email alerts
  • Access to premium INK Research reports
  • Full access to weekly North America Top filer reports
  • Ad-free browsing
  • INK Ultra Money premium content

(already an Ultra member? Please log into your account for access)